• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Interrelations between psychiatric symptoms and drug-induced movement disorder.精神症状与药物性运动障碍之间的相互关系。
J Psychiatry Neurosci. 2006 May;31(3):177-80.
2
[Iatrogenic psychiatric-like symptoms recognition].[医源性类精神症状的识别]
Encephale. 2010 Oct;36(5):417-24. doi: 10.1016/j.encep.2010.01.003. Epub 2010 Mar 6.
3
Global diagnostic ratings compared to DSM-III-R diagnoses in early dyskinesia.与早期运动障碍中DSM-III-R诊断相比的全球诊断评级。
Prog Neuropsychopharmacol Biol Psychiatry. 1994 Mar;18(2):295-310. doi: 10.1016/0278-5846(94)90061-2.
4
The Extrapyramidal Symptom Rating Scale and Its Abbreviated Version: A Critical Review of Clinimetric Properties.锥体外系症状评定量表及其简表:计量学特性的批判性评价。
Psychother Psychosom. 2023;92(6):359-366. doi: 10.1159/000535113. Epub 2023 Dec 7.
5
Long-Term Safety and Tolerability of Valbenazine (NBI-98854) in Subjects with Tardive Dyskinesia and a Diagnosis of Schizophrenia or Mood Disorder.缬苯那嗪(NBI-98854)在患有迟发性运动障碍且诊断为精神分裂症或心境障碍的受试者中的长期安全性和耐受性。
Psychopharmacol Bull. 2017 Aug 1;47(3):61-68.
6
The incidence of negative symptoms in early schizophrenia, mania and other psychoses.早期精神分裂症、躁狂症及其他精神病中阴性症状的发生率。
Acta Psychiatr Scand. 1989 Jun;79(6):613-8. doi: 10.1111/j.1600-0447.1989.tb10310.x.
7
[The treatment of psychopathologic disorders associated with tardive dyskinesias].[迟发性运动障碍相关精神病理障碍的治疗]
Encephale. 1988 Sep;14 Spec No:241-9.
8
Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia.慢性精神分裂症中的阴性症状、迟发性运动障碍和抑郁
Br J Psychiatry Suppl. 1989 Nov(7):99-103.
9
Early dyskinesia--vulnerability.
Psychopharmacology (Berl). 1992;107(4):503-10. doi: 10.1007/BF02245263.
10
Schizoaffective disorder: a form of schizophrenia or affective disorder?分裂情感性障碍:精神分裂症的一种形式还是情感障碍?
J Clin Psychiatry. 1999 Dec;60(12):874-82.

引用本文的文献

1
Extrapyramidal side effects in first-episode schizophrenia treated with flupenthixol decanoate.癸酸氟哌噻吨治疗首发精神分裂症的锥体外系副作用。
S Afr J Psychiatr. 2021 Jan 11;27:1568. doi: 10.4102/sajpsychiatry.v27i0.1568. eCollection 2021.
2
Decreased Gray Matter Volume of Cuneus and Lingual Gyrus in Schizophrenia Patients with Tardive Dyskinesia is Associated with Abnormal Involuntary Movement.精神分裂症迟发性运动障碍患者楔叶和舌回灰质体积减少与异常不自主运动有关。
Sci Rep. 2018 Aug 27;8(1):12884. doi: 10.1038/s41598-018-31186-y.
3
Gray matter abnormalities in schizophrenia patients with tardive dyskinesia: a magnetic resonance imaging voxel-based morphometry study.精神分裂症伴迟发性运动障碍患者的灰质异常:基于体素的磁共振成像形态测量研究。
PLoS One. 2013 Aug 15;8(8):e71034. doi: 10.1371/journal.pone.0071034. eCollection 2013.
4
Quantifying clinical relevance in the treatment of schizophrenia.量化精神分裂症治疗中的临床相关性。
Clin Ther. 2011 Dec;33(12):B16-39. doi: 10.1016/j.clinthera.2011.11.016.
5
Anticholinergic use in children and adolescents after initiation of antipsychotic therapy.抗胆碱能药物在儿童和青少年开始抗精神病药物治疗后的应用。
Ann Pharmacother. 2010 Jul-Aug;44(7-8):1171-80. doi: 10.1345/aph.1M643. Epub 2010 Jun 29.
6
The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs.寻找抗抑郁药、抗焦虑药、抗精神病药和抗惊厥药的新的未标记适应症。
J Psychiatry Neurosci. 2006 May;31(3):168-76.

本文引用的文献

1
Manual for the Extrapyramidal Symptom Rating Scale (ESRS).锥体外系症状评定量表(ESRS)手册。
Schizophr Res. 2005 Jul 15;76(2-3):247-65. doi: 10.1016/j.schres.2005.02.013. Epub 2005 Apr 18.
2
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): cross-scale comparison in assessing tardive dyskinesia.异常不自主运动量表(AIMS)与锥体外系症状评定量表(ESRS):评估迟发性运动障碍的跨量表比较
Schizophr Res. 2005 Sep 15;77(2-3):119-28. doi: 10.1016/j.schres.2005.03.008.
3
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients.国际自杀预防试验(interSePT):一项比较氯氮平和奥氮平降低精神分裂症及分裂情感性障碍患者自杀行为相对能力的试验的原理与设计
Schizophr Bull. 2004;30(3):577-86. doi: 10.1093/oxfordjournals.schbul.a007102.
4
New nomenclature for drug-induced movement disorders including tardive dyskinesia.包括迟发性运动障碍在内的药物性运动障碍的新命名法。
J Clin Psychiatry. 2004;65 Suppl 9:9-15.
5
A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia.关于精神分裂症患者依从性、长效肌内注射抗精神病药物及新型长效注射用非典型抗精神病药物利培酮的综述
Eur Neuropsychopharmacol. 2004 Mar;14(2):87-92. doi: 10.1016/S0924-977X(03)00109-3.
6
Treatment of schizophrenia with long-acting injectable risperidone: a 12-month open-label trial of the first long-acting second-generation antipsychotic.长效注射用利培酮治疗精神分裂症:首个长效第二代抗精神病药物的12个月开放标签试验。
J Clin Psychiatry. 2003 Oct;64(10):1250-7. doi: 10.4088/jcp.v64n1017.
7
Long-acting injectable risperidone: efficacy and safety of the first long-acting atypical antipsychotic.长效注射用利培酮:首个长效非典型抗精神病药物的疗效与安全性。
Am J Psychiatry. 2003 Jun;160(6):1125-32. doi: 10.1176/appi.ajp.160.6.1125.
8
Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).氯氮平治疗精神分裂症患者的自杀倾向:国际自杀预防试验(InterSePT)。
Arch Gen Psychiatry. 2003 Jan;60(1):82-91. doi: 10.1001/archpsyc.60.1.82.
9
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials.利培酮对通过因子分析得出的精神分裂症五个维度的影响:北美试验的综合结果。
J Clin Psychiatry. 1997 Dec;58(12):538-46. doi: 10.4088/jcp.v58n1205.
10
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients. A re-evaluation of the North American risperidone study.
Eur Arch Psychiatry Clin Neurosci. 1995;245(1):45-9. doi: 10.1007/BF02191543.

精神症状与药物性运动障碍之间的相互关系。

Interrelations between psychiatric symptoms and drug-induced movement disorder.

作者信息

Chouinard Guy

机构信息

Clinical Psychopharmacology Unit, Allan Memorial Institute, McGill University Health Centre, McGill University, Montréal, Que, Canada.

出版信息

J Psychiatry Neurosci. 2006 May;31(3):177-80.

PMID:16699603
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1449877/
Abstract

After 30 years of clinical research into drug-induced movement disorder (DIMD), we are still facing unresolved issues regarding the interrelations between psychiatric symptoms and DIMD. Recently, I proposed a new classification of DIMD that includes abnormal movements previously labelled extrapyramidal symptoms. DIMD caused by psychotropic drugs is still confused with psychiatric symptoms treated by the same drugs. The results from 2 international multicentre trials, the InterSePT and the Ris-Consta Studies, conducted in the era of both typical and atypical antipsychotic agents, which included over 3,000 patients with schizophrenia and schizoaffective disorder worldwide, still showed a high, but decreasing, incidence of pretreatment DIMD, which varied from 57.5% (1998-1999) to 47.4% (1999-2000), and a decreasing incidence of tardive dyskinesia, which varied from 12% (1998-1999) to 10.2% (1999-2000), reflecting the greater use of atypical antipsychotic drugs. Furthermore, in both studies, psychiatric symptoms as measured by the Positive and Negative Symptom Scale (PANSS) were significantly correlated with DIMD and DIMD subtypes, thus suggesting the need for additional measurement instruments in schizophrenia and related psychoses.

摘要

在对药物性运动障碍(DIMD)进行了30年的临床研究之后,我们在精神症状与DIMD之间的相互关系方面仍面临未解决的问题。最近,我提出了一种新的DIMD分类方法,其中包括以前被称为锥体外系症状的异常运动。精神药物引起的DIMD仍与同一药物治疗的精神症状相混淆。在典型和非典型抗精神病药物时代进行的两项国际多中心试验,即InterSePT和Ris-Consta研究,涉及全球3000多名精神分裂症和分裂情感性障碍患者,结果仍显示治疗前DIMD的发生率较高,但呈下降趋势,从57.5%(1998 - 1999年)降至47.4%(1999 - 2000年),迟发性运动障碍的发生率也在下降,从12%(1998 - 1999年)降至10.2%(1999 - 2000年),这反映了非典型抗精神病药物的使用增加。此外,在这两项研究中,用阳性和阴性症状量表(PANSS)测量的精神症状与DIMD及其亚型显著相关,因此表明在精神分裂症和相关精神病中需要额外的测量工具。